Clinical evidence

The Empower+ app, powered by HealthGen's unified biomarker platform, is clinically validated through randomised controlled trials and real-world implementation studies across Singapore's healthcare system.

Randomised Controlled Trial

EMPOWER Trial

997 adults with type 2 diabetes in Singapore randomised to Empower+ app + wearable versus usual care.

Intervention group achieved significantly greater HbA1c reduction and improved patient activation scores.

3 months
0.80%
vs 0.49% control
12 months
1.15%
vs 0.67% control
HbA1c Reduction (%)
3 months
Intervention
0.80%
Control
0.49%
12 months
Intervention
1.15%
Control
0.67%
Intervention Components & Outcomes
Full intervention (n=201)
App • Wearable • CGM • Coaching
Higher response rateGreater HbA1c reduction
Digital-only (n=199)
App • Wearable
Meaningful improvement

Both arms showed improvement, with the full intervention achieving higher proportions of clinically significant HbA1c reduction

Comparative Effectiveness Trial

CARE Trial

400 adults with type 2 diabetes randomised to compare full intervention (app + wearable + CGM + coaching) versus digital-only (app + wearable).

Both arms improved HbA1c, but the full intervention arm showed larger within-arm reductions and a higher proportion achieving clinically significant improvement.

201 participants: Empower+ app, wearable, CGM, coaching
199 participants: Empower+ app and wearable only
Endpoints assessed at 12 and 24 weeks
Progress Report, May 2025

Ready to unify your digital biomarkers?

See how HealthGen can help you ship faster, scale further, and get to insights without rebuilding the stack.